Shares of Sientra, Inc. (NASDAQ: SIEN) soars more than 86% during pre-market trading on Friday. This surge can be attributed to Sientra’s announcement that the Food and Drug Administration (FDA) has granted a 510k-clearance for their highly innovative product, the AlloX2 Pro Tissue Expander.
Sientra has achieved a significant milestone by utilizing its proprietary dual port technology. This technology was initially introduced in the groundbreaking AlloX2 tissue expander. The AlloX2 Pro takes this technology to new heights by eliminating a staggering 95% of the metal typically associated with tissue expander ports. This breakthrough allows the AlloX2 Pro to be labeled as MRI-conditional, making it the first and only tissue expander approved in the United States for exposure to magnetic resonance imaging (MRI). This is a crucial development for breast reconstruction patients, as MRI serves as an important screening tool.
The AlloX2 Pro offers several other innovative features that enhance patient outcomes. One notable feature is its minimal interference with radiation therapy for post-mastectomy patients, ensuring optimal treatment. In addition, the AlloX2 Pro enables faster port filling and drainage, improving the efficiency of the procedure. Lastly, patients can enjoy enhanced comfort through the inclusion of a softer drain.